287 related articles for article (PubMed ID: 32377699)
21. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
22. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.
Feng W; Huang W; Chen J; Qiao C; Liu D; Ji X; Xie M; Zhang T; Wang Y; Sun M; Tian D; Fan D; Nie Y; Wu K; Xia L
Theranostics; 2021; 11(6):2612-2633. PubMed ID: 33456563
[No Abstract] [Full Text] [Related]
23. Mobilization of endothelial progenitor cells promotes angiogenesis after full thickness excision by AMD3100 combined with G-CSF in diabetic mice by SDF-1/CXCR4 axis.
Lin X; Wang H; Li X
Diab Vasc Dis Res; 2021; 18(2):14791641211002473. PubMed ID: 33779350
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs.
Meister MT; Boedicker C; Graab U; Hugle M; Hahn H; Klingebiel T; Fulda S
Cancer Lett; 2016 Oct; 381(2):287-95. PubMed ID: 27521572
[TBL] [Abstract][Full Text] [Related]
25. Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma.
Miyoshi K; Kohashi K; Fushimi F; Yamamoto H; Kishimoto J; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2014 Sep; 45(9):1900-9. PubMed ID: 25086956
[TBL] [Abstract][Full Text] [Related]
26. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
27. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
Miekus K; Lukasiewicz E; Jarocha D; Sekula M; Drabik G; Majka M
Cell Death Dis; 2013 Jan; 4(1):e459. PubMed ID: 23328666
[TBL] [Abstract][Full Text] [Related]
28. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
29. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 Regulates Temporal Differentiation via PRC1 Complex in Organogenesis of Epithelial Glands.
Kim J; Lee SW; Park K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435128
[TBL] [Abstract][Full Text] [Related]
31. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
[TBL] [Abstract][Full Text] [Related]
32. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
33. The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
Xing L; Lv HT; Liu SG; Wang WB; Zhang TF; Liu JH; Bian W
Scand J Gastroenterol; 2021 Aug; 56(8):914-919. PubMed ID: 34165373
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
[TBL] [Abstract][Full Text] [Related]
36. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
37. Suppression of the SDF‑1/CXCR4/β‑catenin axis contributes to bladder cancer cell growth inhibition in vitro and in vivo.
Zhang T; Yang F; Li W; Liu B; Li W; Chen Z; Wang C
Oncol Rep; 2018 Sep; 40(3):1666-1674. PubMed ID: 30015971
[TBL] [Abstract][Full Text] [Related]
38. The study of targeted blocking SDF-1/CXCR4 signaling pathway with three antagonists on MMPs, type II collagen, and aggrecan levels in articular cartilage of guinea pigs.
Wang G; Li Y; Meng X; Yang X; Xiang Y
J Orthop Surg Res; 2020 May; 15(1):195. PubMed ID: 32471458
[TBL] [Abstract][Full Text] [Related]
39. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
[TBL] [Abstract][Full Text] [Related]
40. CXCL12/CXCR4 axis as a key mediator in atrial fibrillation via bioinformatics analysis and functional identification.
Liu P; Sun H; Zhou X; Wang Q; Gao F; Fu Y; Li T; Wang Y; Li Y; Fan B; Li X; Jiang T; Qin X; Zheng Q
Cell Death Dis; 2021 Aug; 12(9):813. PubMed ID: 34453039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
